Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
You Ke,1 Cheng Xiang2 1Department of Nephrology, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China; 2Department of Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, China Background: Thyroid cancer becomes the most common endocrine cancer with the great...
Guardado en:
Autores principales: | Ke Y, Xiang C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/982fc76b45f340d6a995fcae8a006fdd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
por: Maciej Ratajczak, et al.
Publicado: (2021) -
Curculigoside Ameliorates Bone Loss by Influencing Mesenchymal Stem Cell Fate in Aging Mice
por: Na Wang, et al.
Publicado: (2021) -
Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma
por: Xue H, et al.
Publicado: (2017) -
Fabricating polydopamine-coated MoSe2-wrapped hollow mesoporous silica nanoplatform for controlled drug release and chemo-photothermal therapy
por: Chai S, et al.
Publicado: (2018) -
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid
por: Li ZY, et al.
Publicado: (2020)